References
- World Health Organization. Novel Coronavirus Situation Reports 2020. 2020 [2020 Apr 10]. Available from: https://covid19.who.int
- Ladda M, Lynde C, Fleming P. Severe acute respiratory syndrome coronavirus 2 and the use of biologics in patients with psoriasis. J Cutan Med Surg. 2020;24:625–632.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
- D'Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21–28.
- Kohmer N, Westhaus S, Rühl C, et al. Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity. bioRxiv. 2020.
- Dopytalska K, Mikucka-Wituszynska A, Ciechanowicz P, et al. Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw. J Dermatolog Treat. 2020.
- The American Academy of Dermatology. Guidance on the use of medications during COVID-19 outbreak. 2020 [updated 2020 Apr 14]. Available from: https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics
- European Academy of Dermatology and Venereology. Management of psoriasis patients under systemic treatments. 2020. Available from: https://eadv.org/covid-19/task-force
- Canadian Dermatology Association. Patient information: COVID & systemics. 2020 [2020 May 14]. Available from: https://dermatology.ca/public-patients/covid-19-systemics/
- International League of Dermatological Societies. Guidance on the use of systemic therapy for patients with psoriasis/atopic dermatitis during the COVID-19 (SARS-CoV-2, coronavirus) pandemic. 2020 [updated 2020 May]. Available from: https://ilds.org/covid-19/guidance-psoriasis-atopic-dermatitis/